First human tests begin for potential new pain drug
NCT ID NCT05547503
Summary
This early study tested a new oral drug called AFA-281 in healthy volunteers to see if it is safe and how the body processes it. The study had two parts: first giving single doses, then giving multiple daily doses for up to three weeks. Researchers measured side effects, heart function, and drug levels in the blood to gather basic safety information.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAIN, NEUROPATHIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CenExcel CNS
Los Alamitos, California, 90720, United States
Conditions
Explore the condition pages connected to this study.